Literature DB >> 30344146

Treatment response in osmotic demyelination syndrome presenting as severe parkinsonism, ptosis and gaze palsy.

Sanihah Abdul Halim1, Nur Aida Mohd Amin2.   

Abstract

Osmotic demyelination syndrome commonly affects the pons and infrequently involves the extrapontine region. We report a patient with severe hyponatraemia who developed osmotic demyelination syndrome as a consequence of rapid sodium correction. The condition manifested as acute severe parkinsonism, bilateral ptosis and gaze impairment. MRI revealed typical features of central pontine and extrapontine myelinolysis. The patient improved gradually after treatment with a combination of levodopa, intravenous immunoglobulin and dexamethasone. However, it is important to emphasise that the improvement of neurological symptoms is not necessarily causal with these experimental therapies. © BMJ Publishing Group Limited 2018. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  brain stem / Cerebellum; fluid electrolyte and acid-base disturbances; parkinson’s disease; unwanted effects / adverse reactions

Mesh:

Substances:

Year:  2018        PMID: 30344146      PMCID: PMC6202983          DOI: 10.1136/bcr-2018-225751

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  28 in total

Review 1.  Treatment of hyponatremia.

Authors:  Richard H Sterns; John Kevin Hix; Stephen Silver
Journal:  Curr Opin Nephrol Hypertens       Date:  2010-09       Impact factor: 2.894

2.  Central pontine myelinolysis: case series and review.

Authors:  A Kenneth Musana; Steven H Yale
Journal:  WMJ       Date:  2005-08

3.  Astrocytes are an early target in osmotic demyelination syndrome.

Authors:  Fabrice Gankam Kengne; Charles Nicaise; Alain Soupart; Alain Boom; Johan Schiettecatte; Roland Pochet; Jean Pierre Brion; Guy Decaux
Journal:  J Am Soc Nephrol       Date:  2011-09-01       Impact factor: 10.121

Review 4.  The hyponatremic patient: a systematic approach to laboratory diagnosis.

Authors:  Haralampos J Milionis; George L Liamis; Moses S Elisaf
Journal:  CMAJ       Date:  2002-04-16       Impact factor: 8.262

Review 5.  Extrapontine Myelinolysis in a patient with Primary Adrenal Insufficiency.

Authors:  Jr-Wei Wu; Pei-Ning Wang; Jiing-Feng Lirng; Ruei-Wen Hsu; Wei-Ta Chen
Journal:  Acta Neurol Taiwan       Date:  2014-12

6.  Severe hyponatraemia during therapy with ramipril.

Authors:  I Ramasamy
Journal:  BMJ Case Rep       Date:  2009-09-15

7.  "Man-in-the-barrel" syndrome as delayed manifestation of extrapontine and central pontine myelinolysis: beneficial effect of intravenous immunoglobulin.

Authors:  Dirk Deleu; Khalid Salim; Boulenouar Mesraoua; Abbas El Siddig; Hassan Al Hail; Yolande Hanssens
Journal:  J Neurol Sci       Date:  2005-10-15       Impact factor: 3.181

8.  Hyponatremia treatment guidelines 2007: expert panel recommendations.

Authors:  Joseph G Verbalis; Stephen R Goldsmith; Arthur Greenberg; Robert W Schrier; Richard H Sterns
Journal:  Am J Med       Date:  2007-11       Impact factor: 4.965

9.  DDAVP is effective in preventing and reversing inadvertent overcorrection of hyponatremia.

Authors:  Anjana Perianayagam; Richard H Sterns; Stephen M Silver; Marvin Grieff; Robert Mayo; John Hix; Ruth Kouides
Journal:  Clin J Am Soc Nephrol       Date:  2008-01-30       Impact factor: 8.237

Review 10.  Movement disorders and the osmotic demyelination syndrome.

Authors:  Aaron de Souza
Journal:  Parkinsonism Relat Disord       Date:  2013-05-07       Impact factor: 4.891

View more
  2 in total

1.  Dramatic Response to Pramipexole in Delayed-Onset Parkinsonism from Osmotic Demyelinating Syndrome.

Authors:  Steve C Han; Linn Katus; Steven Frucht
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2020-06-16

2.  Hyponatremia and extrapontine myelinolysis in a patient with COVID-19: A case report.

Authors:  Muhammad Abd Ur Rehman; Abdulrahman Fadhl Abdulrahman; Aariz Zainab; Yahya Paksoy; Nadir Kharma
Journal:  Clin Case Rep       Date:  2021-07-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.